Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Stoke Therapeutics, Inc.
13D/A
Amendment 6
STOK · 86150R107
|
4.1% |
8/26/2025
Event 8/22/2025
|
|||
| Blue Horizon Enterprise Ltd | 3.6% | ||||
| Ezbon International Ltd | 0.5% | ||||
| Montrago Trustees Ltd | 4.1% | ||||
| Skorpios Trust | 4.1% | ||||
|
Stoke Therapeutics, Inc.
13D/A
Amendment 5
STOK · 86150R107
|
6.0% |
6/23/2025
Event 6/18/2025
|
|||
| Blue Horizon Enterprise Ltd | 5.4% | ||||
| Ezbon International Ltd | 0.5% | ||||
| Montrago Trustees Ltd | 6.0% | ||||
| Skorpios Trust | 6.0% | ||||
|
Stoke Therapeutics, Inc.
13D/A
Amendment 4
STOK · 86150R107
|
7.2% |
6/6/2025
Event 6/4/2025
|
|||
| Blue Horizon Enterprise Ltd | 5.4% | ||||
| Ezbon International Ltd | 1.7% | ||||
| Montrago Trustees Ltd | 7.2% | ||||
| Skorpios Trust | 7.2% | ||||
|
Stoke Therapeutics, Inc.
13D/A
Amendment 3
STOK · 86150R107
|
13.0% |
12/27/2024
Event 12/23/2024
|
|||
| Blue Horizon Enterprise Ltd. | 5.6% | ||||
| Ezbon International Limited | 7.4% | ||||
| Montrago Trustees Limited | 13.0% | ||||
| Skorpios Trust | 13.0% | ||||